1,020 filings
Page 12 of 51
4
p0b7f33wxp4p8k
19 Jun 20
Cardiff Oncology / Rodney S Markin ownership change
4:15pm
4
0kwv5og6
19 Jun 20
Cardiff Oncology / THOMAS PHD ADAMS ownership change
4:15pm
8-K
4dwdpup yk0cucbcvf
19 Jun 20
Departure of Directors or Certain Officers
9:05am
424B5
j24pn 4685ex
17 Jun 20
Prospectus supplement for primary offering
11:54am
8-K/A
7na55xwadzrd3
17 Jun 20
Other Events
12:00am
8-K
2zdw1u
16 Jun 20
Cardiff Oncology Secures $13.5 Million Equity Investment from Biotech-Focused Fundamental Institutional Investors Acorn Bioventures and CAM Capital
4:26pm
8-K
27pxf6tdzjl
15 Jun 20
Other Events
11:50am
8-K
oz1d1dm63gs41dzal56s
9 Jun 20
Other Events
11:26am
SC 13G
p298lu74zxbxkm 09s
4 Jun 20
Cardiff Oncology / ACORN BIOVENTURES ownership change
4:14pm
424B3
e17xxjpatoc ahad
3 Jun 20
Prospectus supplement
4:01pm
EFFECT
q0d6s15bww
3 Jun 20
Notice of effectiveness
12:15am
D
vge30qs08fh47v8i23
1 Jun 20
$2.5M in equity / options / securities to be acquired, sold $2.5M, 1 investor
3:46pm
8-K
02dvb1 8ze
29 May 20
Cardiff Oncology Data Continues to Demonstrate Efficacy of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Cancer Presented at ASCO
12:00pm
CORRESP
0laxb k55jlyw7ocqk
29 May 20
Correspondence with SEC
12:00am
UPLOAD
dyd2kboj
29 May 20
Letter from SEC
12:00am
8-K
1syrr89nfoxn8jhwlk
28 May 20
Cardiff Oncology Announces Fast Track Designation Granted by the FDA to Onvansertib for Second-Line Treatment of KRAS-Mutated Colorectal Cancer
11:50am
424B5
vtaogy2eu0ig3l
27 May 20
Prospectus supplement for primary offering
4:29pm
8-K
k8fd7ho1c
27 May 20
Cardiff Oncology Announces $2.5 Million Equity Investment by Biotech-Focused Fundamental Investor Acorn Bioventures
11:07am
D
2t1 0f8oqqwr79wr
21 May 20
$810K in equity, sold $810K, 8 investors
4:05pm